These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 2479178)

  • 41. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in the biological therapy and gene therapy of malignant disease.
    Hersh EM; Stopeck AT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2623-9. PubMed ID: 10068264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer therapy by biological response modifiers.
    Herberman RB
    Arzneimittelforschung; 1987 Feb; 37(2A):246-50. PubMed ID: 2436633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rational use of biological response modifiers in cancer and related diseases. Transactions from the sixth international San Rocco Cancer Symposium. Pavia, Italy, 11-22 September 1988.
    Med Oncol Tumor Pharmacother; 1989; 6(1):1-113. PubMed ID: 2471024
    [No Abstract]   [Full Text] [Related]  

  • 45. The action of interferons on virus-associated human neoplasms.
    Strander H
    Cancer Surv; 1989; 8(4):755-92. PubMed ID: 2484312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of interferon in clinical practice.
    Sréter L; Fehér J
    Ther Hung; 1991; 39(4):159-66. PubMed ID: 1725832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo.
    Lindner DJ; Borden EC; Kalvakolanu DV
    Clin Cancer Res; 1997 Jun; 3(6):931-7. PubMed ID: 9815768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interferon treatment of human malignancies--a short review.
    Einhorn S; Strander H
    Med Oncol Tumor Pharmacother; 1993; 10(1-2):25-9. PubMed ID: 7505041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications.
    Ferrantini M; Belardelli F
    Semin Cancer Biol; 2000 Apr; 10(2):145-57. PubMed ID: 10936064
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Principles in the biomodulation of cytotoxic drugs by interferons.
    Wadler S; Schwartz EL
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):45-8. PubMed ID: 1373005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical use of biologic response modifiers in cancer treatment: an overview. Part I. The interferons.
    Balmer CM
    DICP; 1990; 24(7-8):761-8. PubMed ID: 1695795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The medical significance of interferons and their inducers].
    Ershov FI
    Vestn Ross Akad Med Nauk; 2004; (2):9-13. PubMed ID: 15101201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical evaluation of treatment with interferon.
    Strander H
    Med Oncol Tumor Pharmacother; 1989; 6(1):87-91. PubMed ID: 2471026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interferon modulates central nervous system function.
    Reyes-Vázquez C; Prieto-Gómez B; Dafny N
    Brain Res; 2012 Mar; 1442():76-89. PubMed ID: 22322149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferons and their role In inflammation.
    Tilg H; Kaser A
    Curr Pharm Des; 1999 Oct; 5(10):771-85. PubMed ID: 10526087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems.
    Bocci V
    Crit Rev Ther Drug Carrier Syst; 1992; 9(2):91-133. PubMed ID: 1378776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The interferons. Mechanisms of action and clinical applications.
    Baron S; Tyring SK; Fleischmann WR; Coppenhaver DH; Niesel DW; Klimpel GR; Stanton GJ; Hughes TK
    JAMA; 1991 Sep; 266(10):1375-83. PubMed ID: 1715409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma.
    Moschos S; Kirkwood JM
    Cytokine Growth Factor Rev; 2007; 18(5-6):451-8. PubMed ID: 17693125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Interferons in medicine].
    Lucivero G
    Recenti Prog Med; 1990 May; 81(5):329-36. PubMed ID: 1696020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NIH conference. Immunomodulators in clinical medicine.
    Fauci AS; Rosenberg SA; Sherwin SA; Dinarello CA; Longo DL; Lane HC
    Ann Intern Med; 1987 Mar; 106(3):421-33. PubMed ID: 2433978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.